Boston builds DES (drug-eluting stent) business with bioresorbable stent
This article was originally published in Clinica
Having successfully taken on the drug-eluting stent (DES) market with Taxus Express2, Boston Scientific is wasting no time in reinforcing its arsenal with a new-generation DES. The company has made an equity investment in REVA Medical, as well as securing an exclusive option to buy the private, San Diego-based developer of bioresorbable stents. Details of the agreement were not disclosed.
You may also be interested in...
Dispatches from a world turned upside down include FDA expressing confidence in Chinese manufacturers – to make their GDUFA payments; projections of drug shortages for ventilator patients; and the launch of new hydroxychloroquine studies.
A Phase III trial testing the antibody-drug conjugate sacituzumab govitecan was stopped early for efficacy, boding well for the BLA pending at the US FDA.
Deal Snapshot: Six companies seek to collect convalescent plasma from COVID-19 survivors to quickly develop hyperimmune immunoglobulin therapy for serious complications of the virus.